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Departments of Chemistry and Chemical Biology, Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, CanadaABSTRACT A promising strategy to control the aggregation of the Alzheimer’s Ab peptide in the brain is the clearance of Ab
from the central nervous system into the peripheral blood plasma. Among plasma proteins, human serum albumin plays a critical
role in the Ab clearance to the peripheral sink by binding to Ab oligomers and preventing further growth into fibrils. However, the
stoichiometry and the affinities of the albumin-Ab oligomer interactions are still to be fully characterized. For this purpose, here
we investigate the Ab oligomer-albumin complexes through a novel and generally applicable experimental strategy combining
saturation transfer and off-resonance relaxation NMR experiments with ultrafiltration, domain deletions, and dynamic light scat-
tering. Our results show that the Ab oligomers are recognized by albumin through sites that are evenly partitioned across the
three albumin domains and that bind the Ab oligomers with similar dissociation constants in the 1–100 nM range, as assessed
based on a Scatchard-like model of the albumin inhibition isotherms. Our data not only explain why albumin is able to inhibit
amyloid formation at physiological nM Ab concentrations, but are also consistent with the presence of a single high affinity
albumin-binding site per Ab protofibril, which avoids the formation of extended insoluble aggregates.INTRODUCTIONThe Alzheimer’s Ab peptide is produced not only in the
central nervous system (CNS) but also in most cells of
peripheral tissues (1). Removal of the Ab peptide from the
CNS to the periphery through the blood brain barrier has
been proposed as an effective strategy to prevent the Ab
accumulation in the brain (1). Specifically, according to
the peripheral sink hypothesis, blood plasma proteins,
such as human serum albumin (HSA), control Ab aggrega-
tion within the brain from the periphery, by regulating the
equilibrium of Ab peptide across the blood brain barrier.
Therefore, it is likely that plasma protein dysfunctions affect
the clearance of Ab from the CNS and consequently Ab pla-
que deposition within the brain. For instance, recent clinical
studies show that low albumin levels are associated with
increased odds of cognitive impairment and, moreover, indi-
cate the use of albumin in plasma exchange therapies as
a promising avenue in the treatment of mild to moderate
Alzheimer’s disease (2,3). Furthermore, HSA is also an
effective inhibitor of Ab fibrilization (4–7).
Despite the clinical relevance of albumin in the context of
Alzheimer’s disease, several fundamental questions about
the nature of the HSA-Ab interactions are still open.
Although it has been suggested that albumin preferentially
targets Ab oligomers rather than monomers through capping
of exposed hydrophobic sites (4), considerable uncertainty
remains on the stoichiometries and on the affinities of
HSA-Ab binding (5–9). Here we report both the prevailing
binding stoichiometries and the domain-specific binding
affinities for the Ab/HSA system.Submitted September 24, 2010, and accepted for publication November 18,
2010.
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0006-3495/11/01/0183/10 $2.00HSA is composed of three domains (Fig. 1 a) and the
distribution of binding sites across the three HSA domains
varies widely for different albumin ligands (10). For in-
stance, nonesterified fatty acids (FAs) are one of the primary
physiological HSA ligands and their binding involves up to
seven binding sites, three of which are confined within
domain 3 whereas the other four are in domains 1 and 2
(Fig. 1 a) (10,11). Unlike FAs, exogenous amphiphilic drugs
bind HSA at sites that do not involve all three domains (10).
Specifically, ibuprofen-like drugs with aromatic carboxyl-
ates in an extended conformation display a marked
selectivity for Sudlow’s site II in domain 3, whereas
warfarin-like drugs with a bulky heterocyclic anion bind
preferentially Sudlow’s site I in domain 2. Within this range
of possible binding stoichiometries, it is currently unknown
whether the recognition of Ab oligomers by HSA
approaches more closely the three-domain binding pattern
of fatty acids or the domain-selective interactions displayed
by several drugs.
Furthermore, only partial characterizations are available
for the binding affinities of the HSA-Ab assembly
complexes (4,7,8). Based on measured half-maximal inhib-
itory protein concentration (IC50 values) for the competitive
inhibition by HSA of the incorporation of Ab monomers
into preformed fibrils, a broad upper limit of ~10 mM for
the Ab assembly-HSA dissociation constants has been
proposed (7,8). It is therefore still unclear whether the Ab
oligomer-HSA KD values are in the mM or in the nM range,
which would be more comparable to the physiological nM
concentration of the Ab peptide in human plasma (1). In
addition, due to the presence of a distribution of Ab olig-
omer sizes and possibly of binding stoichiometries (12), it
is also unknown if and how the Ab oligomer-HSA KD values
vary among the three domains of HSA.doi: 10.1016/j.bpj.2010.11.037
FIGURE 1 Domain organization of HSA and design of the HSA
constructs used in this investigation. (a) Ribbon diagram of the HSA struc-
ture in the fatty acid bound state (PDB file1E7H) (11). Palmitate molecules
are shown in space-filling representation to indicate fatty acid binding sites.
Domain 1 contains FA1 and FA2 binding sites, while domain 2 contains
FA6 and FA7 binding sites. Domain 3 contains FA 3-5 binding sites.
Drug binding sites are indicated as Sudlow sites 1 and 2, and their represen-
tative drug ligands are listed (10). (b) Constructs used in this study.
184 Milojevic and MelaciniTo investigate the Ab oligomer-HSA binding stoichiom-
etries and domain-specific binding affinities, we have devel-
oped an integrated experimental strategy based on saturation
transfer difference (STD) (4,13,14) and off-resonance relax-
ation (15,16) NMR experiments aimed at quantitatively
comparing the Ab oligomerization inhibitory potencies of
different HSA deletion constructs. Our comparative NMR
analyses have primarily focused on the Ab (12–28) peptide,
which not only spans the central hydrophobic core of the Ab
peptide (L17VFFA21) and key HSA binding sites (5), but it is
also known to provide a reliable and stable model for the Ab
oligomers (17–19). However, whenever possible, the results
obtained for Ab (12–28) were validated using the longer Ab
(1–42) peptide.
Our data indicate an even partitioning of largely indepen-
dent Ab oligomer-binding sites across the three HSA
domains, with similar affinities in the submicromolar range.
In addition, the presence of a single high affinity albumin-
binding site per Ab oligomer/protofibril was established
through dynamic light scattering (DLS) measurements,
which, unlike NMR, are sensitive to small populations of
high molecular weight (MW) species. We anticipate thatBiophysical Journal 100(1) 183–192the experimental strategies proposed here will be useful
for the characterization of complex stoichiometries and
relative affinities in other systems involving oligomerization
inhibitory proteins and amyloidogenic peptides that self-
associate into a distribution of oligomers with heterogenous
sizes (12).MATERIALS AND METHODS
See the Supporting Material.RESULTS
HSA domain dissection approach
Our experimental design aimed at defining the partitioning
of the Ab oligomer binding sites across the three HSA
domains and at dissecting the HSA domain contributions
to the inhibition of the Ab oligomerization relies on five
protein constructs (Fig. 1 b). Besides full-length HSA, these
include one-domain and two-domain HSA deletion mutants
(Fig. 1 b). The one-domain segments include domains 1 and
3, which are soluble in isolation. However, domain 2 is only
marginally soluble when isolated from HSA (20) and there-
fore it was expressed and purified as part of a pair of two-
domain constructs (i.e., 12 and 23, Fig. 1 b), in which the
fusion to either domain 1 or 3 ensures the required solu-
bility. The inhibitory efficiency of domain 2 with respect
to the Ab oligomerization can then be assessed through
the comparative analysis of the one- and two-domain
constructs. The structural integrity of the five HSA con-
structs in Fig. 1 b was confirmed by circular dichroism spec-
troscopy (Eq. S2, Fig. S1, and Table S1 in the Supporting
Material).All three HSA domains contain Ab oligomer
binding sites and inhibit Ab oligomer formation
The oligomerization inhibitory properties of the five HSA
constructs shown in Fig. 1 bwere initially qualitatively eval-
uated through simple one-dimensional NMR spectra of the
model peptide Ab (12–28), as illustrated in Fig. 2. The refer-
ence spectrum of the filtered Ab (12–28) (Fig. 2 a) was
acquired first and is characterized by narrow line-widths
as expected for a largely monomeric Ab peptide (4). As
previously indicated (4), addition of 25 mM NaCl to the
filtered Ab (12–28) results in signal broadening of most
resonances (Fig. 2 b) (4) due to screening of repulsive inter-
molecular electrostatic interactions and hydrophobic-
collapse-driven oligomerization. The signal broadening
observed in Fig. 2 b is therefore a result of the exchange
of polypeptide chains between the monomeric and the olig-
omeric states of Ab (12–28). Albumin interferes with this
chemical exchange phenomenon and results in a marked
line sharpening (Fig. 2 c). The Ab (12–28) line sharpening
FIGURE 2 Effect of wt HSA and its deletion mutants on the one-dimen-
sional NMR spectra of the Ab (12–28) peptide. (a) Spectrum of 30 kDa
filtered 1 mM Ab (12–28). (b) Addition of 25 mM NaCl causes significant
aggregation as indicated by line broadening and intensity losses. (c–g)
Effect of the addition of HSA and its deletion mutants: domains 12 and
23 and domains 3 and 1, respectively. A similar line sharpening is obtained
upon addition of all protein constructs. (Dotted lines and arrows) Compar-
ison of the one-dimensional intensities between different spectra; although
protein addition results in line sharpening, it does not result in the restora-
tion of the starting signal intensity. Spectra a–c were previously published
elsewhere (4) and are reported here only for comparison purposes.
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cific Ab interactions with HSA, because control proteins
(i.e., insulin and lysozyme) did not result in any detectable
line-width change (Fig. S2).
A closer inspection to the spectra in Fig. 2, a–c, indicates
that, although HSA sharpens several peaks to line-widths
comparable with those of the filtered sample, HSA is unable
to restore the NMR signal intensities to those of the original
filtered Ab (12–28) sample before the salt-induced oligomer
formation (Fig. 2 a). This observation points to a signifi-
cantly lower population of the monomeric states in the
samples with HSA relative to the filtrated solution and has
been rationalized in terms of a Ab monomer competitor
inhibitory mechanism, whereby HSA does not revert the
oligomerization equilibria back to the monomeric peptide,
but binds the Ab oligomers and blocks their growth (4).
When similar experiments are repeated with the HSA
deletion mutants, i.e., corresponding to domains 1, 3, 12,
and 23 (Fig. 1 b), a line sharpening comparable to that
observed after the addition of wt HSA is observed (Fig. 2,
d–g). These observations indicate that both domains 1 and
3 contain Ab oligomer binding sites and they are able to
inhibit Ab oligomerization through the Ab monomercompetitor inhibitory mechanism. Nonetheless, based on
these data alone, no firm conclusions can be inferred about
the inhibitory function of domain 2, because at this point we
cannot rule out that the line-sharpening effect detected for
the two-domain constructs (Fig. 2, d and e) is mainly due
to domains 1 and 3.
The results obtained in Fig. 2 for the Ab (12–28) peptide
are in full agreement with the inhibitory profiles measured
for the full-length Ab peptide spanning residues 1–42, for
which self-association was monitored both in the absence
and presence of wild-type HSA and of several HSA deletion
mutants. The self-assembly of Ab (1–42) into NMR-
undetectable oligomers, protofibrils, and fibrils was fol-
lowed over time through the simple loss in one-dimensional
NMR signal intensity (Fig. S3). Fig. S3 a shows that, in the
absence of oligomerization inhibitors, >50% of the original
one-dimensional signal is lost already after 11 h from
sample preparation. Conversely, in the presence of substoi-
chiometric amounts of HSA, this decay is dramatically
quenched (Fig. S3 b) and a similar effect is observed for
substoichiometric amounts of the HSA deletion mutants
(Fig. S3, c–e), confirming that domains 1 and 3 include
Ab binding sites and preserve significant Ab oligomeriza-
tion inhibitory functions even for the full-length Ab peptide.
Therefore, overall the results on the Ab (1–42) peptide
(Fig. S3) corroborate the relevance of the Ab (12–28)
construct and of the related one-dimensional line-width
analysis (Fig. 2).
Furthermore, the Ab (1–42) one-dimensional NMR
spectra acquired immediately after addition of the HSA
constructs do not differ significantly from the spectra of
the Ab (1–42) peptide alone (Fig. S4), confirming that inhi-
bition of Ab fibril formation in the presence of HSA is not
due to interactions with monomeric but with oligomeric
Ab (1–42). However, it is still not possible based on these
data alone to reach a definitive conclusion on the role of
domain 2 in the Ab oligomer inhibition, or to obtain infor-
mation on the dissociation constants of the albumin-Ab
oligomer interactions. To dissect the contributions of the
single domains, more quantitative estimations of the oligo-
merization inhibitory potencies of the different HSA con-
structs is required. For this purpose, one-dimensional STD
data were acquired at increasing protein concentrations
(Fig. 3, b–f), starting from filtered Ab (12–28) samples in
which stable oligomers were induced by salt addition, as
in Fig. 2 b. These STD experiments are less suitable for
the longer Ab (1–42) peptide, because, in this case, the
soluble oligomers in exchange with the NMR-detectable
low-MW species appear only transiently (4,21).
The STD monitored titration data (Fig. 3, b–f) display a
typical dose-response pattern, in which the saturation trans-
fer difference/saturation transfer reference ratios (ISTD/ISTR)
decrease progressively as the protein concentration in-
creases, until a plateau is reached. This dose-response
pattern is observed for full-length HSA (Fig. 3 f) as wellBiophysical Journal 100(1) 183–192
FIGURE 3 Dose-response STD-based profiles for the inhibition of the Ab (12–28) self-association by HSA and its deletion mutants. (a) Effect of different
KD values and of different HSA-binding competent Ab oligomer concentrations on dose-response STD curves simulated according to a Scatchard-like model.
This model assumes full equivalence and independence of all sites in HSA that can bind Ab oligomers. Further details on this model are available in the text.
(b–f) Effect of HSA deletion mutants (i.e., domain 3, domain 1, domains 23 and 13) and wt HSA, respectively, on the relative ISTD/ISTR ratios measured for
the filtered Ab (12–28) peptide aggregated through the addition of 25 mMNaCl. All ratios were normalized to their maximum value measured before protein
addition. (b and c, Dashed and solid lines) Backcalculated dose-response curves using the Scatchard-like model and KD values of 1 and 10 nM, respectively.
(d,Dashed and solid blue lines) Backcalculated dose-response curves using the Scatchard-like model and KD values of 20 and 50 nM, respectively. This range
of KD values is in good agreement with the experimental data measured for the domain 23 construct. (Red lines) Obtained based on the single domain
constructs KD values (1 and 10 nM), assuming that individual domains bind independently, i.e., simply downscaling the one-domain curves of panel
b by a factor of two. (e, f, green and black curves) Computed using the KD values that fit the experimental data. (e, f, orange and blue lines) Obtained based
on the one-domain curves of panel c, assuming fully independent binding of Ab oligomers to two and three domains, i.e., simply downscaling the curves of
panel c by a factor of two or three, respectively.
186 Milojevic and Melacinias for all four HSA deletion mutants (Fig. 3, b–e). Although
no major differences were observed among the HSA
constructs in the plateau heights, which cluster around
a residual basal STD effect corresponding to ~15–18% of
the original value measured in the absence of proteinBiophysical Journal 100(1) 183–192(Fig. 3, b–f), significant domain-dependent variations were
observed in the slope of the initial ISTD/ISTR decay (Fig. 3,
b–f). The latter is quantified in terms of half-maximal inhib-
itory protein concentration (i.e., IC50), corresponding to the
midpoint between the maximum (i.e., initial) ISTD/ISTR
Ab-HSA Stoichiometry and Affinity 187value and the plateau region (Fig. 3, b–f). Notably, Fig. 3, b–
f, shows that the measured IC50 values decrease in an almost
linear progression as the number of domains in the inhibi-
tory HSA constructs increases. Specifically, for both
domains 1 and 3 the IC50 values are ~500 nM (Fig. 3,
b and c), while the IC50 decreases by ~50% (i.e., ~250
nM) for the two-domain constructs (Fig. 3, d and e) and
by ~67% (i.e., ~160 nM) for full-length HSA with all three
domains (Fig. 3 f). These observations point to the presence
of Ab oligomer binding sites within the second HSA domain
and to the equivalence of the three HSA domains in their
efficiency as self-assembly inhibitors under our experi-
mental conditions.
The even partitioning across the three albumin domains
of binding sites for the Ab oligomers revealed by the IC50
analysis suggests the existence of a common oligomer
recognition mode shared by all three HSA domains. To
test this hypothesis, the effect of the HSA deletion mutants
on the oligomeric equilibria of Ab (12–28) was monitored
also through nonselective two-dimensional off-resonance
relaxation experiments with a 35.5 tilt angle, which
provide a sensitive probe of the involvement of each Ab
residue in self-recognition (15,16). Specifically, the
residue-specific variations in Ha-R35.5o,ns rates induced byFIGURE 4 Correlations between the nonselective off-resonance relaxation dat
shown in Fig. 1 b. (Horizontal axes) Differences in residue-specific Ha nonsele
(12–28) sample before and after addition of 10 mM full-length HSA. (a–d, Vertica
of the four HSA deletion mutants (domain 1, domain 3, and domains 12 and 23each HSA deletion mutant were correlated with the corre-
sponding changes in Ha-R35.5o,ns rates caused by full-length
HSA (Fig. 4). As shown in Fig. 4, the nonselective two-
dimensional off-resonance relaxation profiles of both one-
domain and two-domain constructs correlate well with
that of full-length HSA, supporting the hypothesis that all
three domains share a similar Ab (12–28) oligomer recogni-
tion mode.
While the equivalent self-assembly inhibitory efficiency
of the three HSA domains is independently supported by
both the off-resonance relaxation experiments (Fig. 4) and
the relationship between the IC50 values and the number
of domains in the HSA constructs (Fig. 3, b–f), it is impor-
tant to note that the IC50 values or the data in Fig. 4 do not
provide any strict quantification of the affinity between
the HSA domains and the Ab oligomers. For instance, the
IC50 values derived from the STD titration curves depend
on the oligomer concentrations, which in turn depend on the
concentrations of Ab peptide and salt (Fig. S5), and there-
fore can be used only to provide an upper limit for the
dissociation constants (KD) of the Ab oligomer-albumin
complexes. The determination of these KD values requires
a more quantitative modeling of the dose-response inhibi-
tory profiles in Fig. 3, b–f.a of full-length HSA and those measured for the four HSA deletion mutants
ctive off-resonance relaxation rates measured for the aggregated 1 mM Ab
l axes) Variations caused by the addition to the aggregated sample of 10 mM
, respectively).
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transfer on the concentration of inhibitor
The dissociation constant, unlike the IC50 value, is indepen-
dent of the Ab oligomer concentration and therefore
provides a more meaningful descriptor of the affinity of
HSA for the Ab oligomers. To obtain dissociation constant
values for the Ab oligomer-HSA complex, the titration data
of Fig. 3, b–f, were analyzed according to a simple model of
the binding isotherms. The first assumption of this model is
that in the absence of albumin, the NMR STD signal
observed for the monomeric Ab peptide arises from the
saturation of Ab oligomers, here denoted as Abn (4). There-
fore, the STD/STR ratio can be expressed as:
ðSTD=STRÞ½HSA ¼ 0 a ½Ab=ðKD;Ab þ ½AbÞ; (1)
where [Ab] is the concentration of monomeric free Ab and
KD,Ab is the dissociation constant of a single polypeptide
chain of Ab from the Abnþ1 oligomers. It should be empha-
sized that KD,Ab represents just an effective dissociation
constant that captures only the average STD effects of the
heterogeneous distribution of Abn sizes present in solution.
In this respect, the use of a single effective KD,Ab constant as
opposed to several Abn MW-dependent dissociation
constants is a major oversimplification. However, Eq. 1 is
still useful for the interpretation of the data in Fig. 3, b–f,
to the extent that it represents one of the simplest possible
models still able to reproduce the key trends observed in
the experimental data, avoiding overparameterization and
the consequent risk of making line fitting an underdeter-
mined problem. Similar considerations apply for the other
dissociation constants defined below.
Because albumin competes with the Ab monomers for
binding to the Abn oligomers (4), HSA is effectively
modeled as a competitive inhibitor of the interaction
between Ab monomers and oligomers. For the sake of
simplicity, we assume that HSA and the Ab oligomers
bind in a 1:1 ratio with an effective dissociation constant:
KD;HSA ¼ ½HSA½Abn=½HSA : Abn:
The STD/STR ratio is then modeled as
ðSTD=STRÞ½HSAR0 a ½Ab=KD;Ab=ð1 þ ½Ab=KD;Ab
þ ½HSA=KD;HSAÞ:
(2)
Equation 2, however, does not take into account that only
a fraction of the oligomers in solution is HSA-binding-
competent (4,5). It has been shown that only Ab oligomers
larger than a critical MW are able to bind albumin (4,5).
Although the exact MW cutoff for the size of the Ab oligo-
mers that bind HSA is still unknown, it is possible to model
this effect into Eq. 2 by introducing the fraction f of Ab olig-
omers that are not HSA-binding-competent. These smaller
Ab oligomers are not bound by HSA (5) and therefore Eq.
2 becomes:Biophysical Journal 100(1) 183–192ðSTD=STRÞ½HSAR0 að1f Þf½Ab=KD;Ab =ð1þ ½Ab=KD;Ab þ ½HSA=KD;HSAÞg
þ f f½Ab=KD;Ab=ð1 þ ½Ab=KD;AbÞg:
(3)
Equation 3 essentially combines Eqs. 1 and 2 and it can
be further simplified by defining the effective apparent
dissociation constant:
KD;HSA;app: ¼ KD;HSAð1 þ ½Ab=KD;Ab Þ: (4)
KD,HSA,app. as defined in Eq. 4 is an effective equilibrium
constant because the monomeric Ab concentration (i.e.,
[Ab]) is not significantly affected by [HSA], as shown by
the one-dimensional NMR spectra of Ab (12–28) acquired
at different concentrations of albumin (Fig. S6). Using
Eq. 4, and normalizing the (STD/STR)[HSA]>0 ratio through
(STD/STR)[HSA]¼0 as expressed in Eq. 1, Eq. 3 is simplified
to:
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA ¼ 0
¼ f þ ð1 f ÞKD;HSA;app:=

KD;HSA;app: þ ½HSA
 (5)
This equation was used to model the inhibition curves
shown in Fig. 3. In the absence of HSA, Eq. 5 correctly
predicts
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA¼ 0 ¼ 1;
while at saturating concentrations of HSA, i.e.,
½HSA[KD;HSA;app
Eq. 5 reduces to:
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA ¼ 0
¼ f for½HSA[KD;HSA;app: (6)
The fraction f of oligomers that are HSA-binding-incom-
petent is therefore directly readable from the plateau height
of the dose-response inhibition plots of Fig. 3. For interme-
diate concentrations of albumin, it is important to note that,
in Fig. 3, the ratios
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA ¼ 0
are reported as a function of the total HSA concentration
([HSA]Tot) as opposed to the free HSA concentration
([HSA]) used in Eq. 5. However, [HSA] can be easily esti-
mated starting from [HSA]Tot because Eq. 5 indicates that
the normalized STD/STR ratios of Fig. 3 are effectively
modeled by the binding of HSA to the Abn oligomer with
an apparent dissociation constant KD,HSA,app.. [HSA] can
then be computed from [HSA]Tot. using KD,HSA,app. as a
parameter, provided that the total concentration of HSA-
binding competent oligomers (i.e., [Abn]Tot) is known.
[Abn]Tot is determined experimentally from the transition
point between the binding and saturation regions of the
Ab-HSA Stoichiometry and Affinity 189HSA titrations curves of Fig. 3, i.e., from the beginning of
the plateau region. Using the experimentally determined
[Abn]Tot value and KD,HSA,app as a fitting parameter, it is
possible to compute [HSA] for each [HSA]Tot. based on
Eq. S1 (in the Supporting Material). Once [HSA] is known,
the value of
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA ¼ 0
is then calculated through Eq. 5, and compared to the exper-
imental data reported in Fig. 3.
In conclusion, for the case of a 1:1 HSA:Abn oligomer-
binding stoichiometry, the inhibitory dose-response titration
curves of
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA ¼ 0 vs: ½HSATotal
provide three distinct parameters:
1. The height of the plateau represents the fraction f of Abn
oligomers that are not HSA-binding-competent (i.e.f)
2. The [HSA]Tot concentration at which the plateau starts
(i.e., crossing point of binding and saturation regions)
provides the total concentration of Abn oligomers that
are HSA-binding-competent (i.e., [Abn]Tot.)
3. Through fitting, it is possible to obtain the average
apparent dissociation constant of the HSA:Abn oligomer
complexes, KD,HSA,app, which is highly sensitive to the
curvature of the plot in the transition zone between the
binding and saturation regions (Fig. 3 a).
Once the KD,HSA,app value is determined, the actual non-
apparent KD,HSA can be computed using Eq. 4. However, it
should be noted that, in our case, the monomer concentra-
tion [Ab] is in the submillimolar range and under our exper-
imental conditions KD,Ab is expected to be of the order
of mM (17). We therefore expect that, within error,
KD,HSA,app and KD,HSA are in the same concentration range.
If the number of Abn oligomers bound per HSA molecule
(nAbn) is >1, the simplest possible model that accounts for
our experimental data assumes that the multiple Abn olig-
omer binding sites within HSA are all equivalent and inde-
pendent of each other (i.e., Scatchard-like model). In this
case, it is still possible to employ the formalism developed
above leading to Eq. 5 and Eq. S1, provided that the
[HSA]Tot used in Eq. S1 is scaled up according to the
number of Abn oligomers bound per HSA molecule (i.e.,
it is multiplied by nAbn). This is easily appreciated consid-
ering that, if the multiple binding sites are equivalent and
independent of each other, an increase in nAbn is indistin-
guishable from a corresponding increase in the number of
HSA molecules, which are also equivalent and independent
from each other. In other words, an increase in nAbn results
mainly in a rescaling of the horizontal axes of the plots of
Fig. 3, explaining also the linear relationship between the
observed IC50 values and the reciprocal of the number of
domains in each HSA construct used in Fig. 3.In the case the number of HSA molecules bound per Abn
oligomer (nHSA) is >1, we find that the simplest possible
model that accounts for our experimental data assumes,
again in a Scatchard-like manner, that the multiple HSA
binding sites within each Abn oligomer are all equivalent
and independent of each other. And in this case, similarly
to what was mentioned for nAbn > 1, it is still possible to
use Eq. 5 and Eq. S1, but only after rescaling (by an nHSA
factor) the total concentration of HSA-binding competent
Abn oligomers (i.e., [Abn]Tot.). Therefore, an increase in
nHSA results mainly in a rescaling of the horizontal axes
of the plots of Fig. 3, similarly to the effect of decreased
nAbn. This means that, in general terms, the transition point
between the binding and the saturation regions in the
titration curves of Fig. 3 provides only the product of
nHSA/nAbn and [Abn]Tot. and based on the inhibition data
of Fig. 3 alone, is not possible to dissect further the stoichio-
metric ratio, nHSA/nAbn, from [Abn]Tot..
Fig. 3 shows that the experimental profiles
ðSTD=STRÞ½HSAR0=ðSTD=STRÞ½HSA ¼ 0 vs: ½HSAtot
are well reproduced by Eq. 5 and Eq. S1 of our model.
Specifically, KD values of 1–10 nM modeled well the
experimental data measured for the single domain con-
structs (i.e., domain 1 and domain 3) (Fig. 3, b and c), while
for the two-domains constructs, i.e., domain 12 and domain
23, the experimental STD data is in good agreement with KD
values in the range of 50–100 and 20–50 nM, respectively
(Fig. 3, e and d).
Interestingly, these dissociation constant values obtained
for the two-domain constructs are higher than the KD values
measured for the single-domain constructs (blue versus red
and green versus orange curves in Fig. 3, d and e, respec-
tively). A possible interpretation of the increased KD values
observed for the two- versus one-domain constructs is that
binding of Ab oligomers to two-domain constructs is at least
partially inhibited by steric hindrance imposed by binding of
other Ab oligomers to the adjacent domain. No major
changes in the fitted KD values were observed in going
from the two-domain constructs to full-length HSA
(Fig. 3, d–f), confirming that, apart from the pairwise partial
steric hindrance between adjacent domains, the three
domains of albumin bind Ab oligomers independently of
each other and all in the 1–100 nM range.Ab oligomers/protofibrils contain a single high
affinity albumin-binding site
Although the previous analyses clearly support the presence
of several Ab-oligomer binding domains within HSA, they
cannot unambiguously define the number of albumin mole-
cules bound per Ab oligomers/protofibrils. However, the
observation that all three domains of HSA bind Abn oligo-
mers with comparable affinities implies that, if the AbnBiophysical Journal 100(1) 183–192
190 Milojevic and Melaciniassemblies bind more than one albumin molecule, albumin
is expected to function as an effective cross-linker of Abn
oligomers, resulting in the formation of large weblike
networks and possibly in sample precipitation. We did not
observe any visible precipitation upon addition of albumin,
suggesting that polymerlike networks do not form upon
mixing of Ab and HSA. To confirm this initial qualitative
assessment, we performed DLS measurements, which are
ideally suited to detect large molecular assemblies because
the DLS sensitivity increases for larger particle sizes,
allowing the detection of minor populations of high MW
aggregates (22,23).
Fig. 5 illustrates the main results obtained through DLS.
Specifically, a solution of 0.1mMAb (142) freshly prepared
(i.e. without incubation) in the absence of albumin displays an
oligomer size distribution with twomain peaks (Fig. 5 a). The
first peak is centered at 17 nm and is assigned to Ab petamers/
hexamers, which have been proposed as the main building
block of high MW assemblies (22,23). The second peak is
centered at 178 nm and it corresponds to highMWassemblies
(23). After 48 h incubation, the oligomer size distribution of
Ab (1–42) in the absence of albumin evolves to result in
two peaks in the 10–100 nm region and still a single peak in
the 100–1000 nm window, but shifted toward sizes larger
than the original 178 nm (Fig. 5 b).
When the DLS experiments are repeated in the presence
of albumin, the main difference observed without incuba-
tion (Fig. 5 a) is a new peak with a ~3.8 nm radius, which
belongs to excess apo albumin. The two main peaks in theFIGURE 5 Intensity versus size distribution obtained from DLS
measurements of 0.1 mM Ab (1–42) in the presence and absence of
200 mM of HSA. (a) Measurements collected immediately after samples
were prepared. (b) Measurements on the same samples incubated for
48 h at 37C after preparation. (Shaded and solid representations) DLS
profiles in the absence and presence of HSA, respectively. Note that all
measurements were performed using 12-mL volume cells and a Zetasizer
Nano S System (Malvern Instruments, Malvern, Worcestershire, UK) at
25C.
Biophysical Journal 100(1) 183–19210–100 nm and 100–1000 nm regions detected for Ab
(1 42) in the absence of albumin are also observed in
the presence of HSA (Fig. 5 a). After 48 h incubation, a
similar pattern with two main peaks in the 10–100 nm and
100–1000 nm regions is still preserved in the presence of
albumin (Fig. 5 b). This observation supports the absence
of the above-mentioned large polymerlike networks ex-
pected if the Ab assemblies bound more than one HSA
molecule, suggesting that the Ab oligomers/protofibrils
contain only a single high affinity albumin-binding site.
These results are also in agreement with previous electron
microscopy (EM) images of Ab (1–42) recorded at different
time intervals after the addition of HSA (24). In these EM
images, no large MW aggregates were detected in the
presence of albumin (24). The DLS and EM data therefore
consistently support the presence of a unique high affinity
albumin-binding site per Abn oligomers/protofibrils.DISCUSSION
The combined analysis of our STD, off-resonance relaxa-
tion, and DLS data is consistent with a general model
whereby each domain of HSA binds at least one Ab olig-
omer with dissociation constants in the 1–100 nM range
(Fig. 6). In agreement with a previously proposed mono-
mer-competition model (4), each albumin domain binds
the Ab oligomers with a similar recognition mode targeting
sites within the Ab oligomers that would otherwise accept
additional Ab monomers, thus inhibiting further growth of
the Ab assemblies. The interactions of the Ab oligomers
with different HSA domains appear to be, to a large extent,
independent of each other, in as much as the experimental
STD-based dose-response curves of Fig. 3 are in good
agreement with a Scatchard-like model assuming full equiv-
alence and independence for the multiple albumin sites that
bind Ab oligomers. However, the slight but significant
increase in KD values observed in going from the one- to
the two-domain constructs (Fig. 3, b–e) is consistent with
some degree of cross-talk arising from steric hindrance
between adjacent domains. Despite its simplicity, this model
leads to three notable implications.
First, the even partitioning of the Ab oligomer binding
sites across the three domains of albumin suggests that
HSA recognizes the Ab assemblies quite differently from
most drugs, which either target Sudlow’s site I or II of
HSA (Fig. 1 a). The presence of Ab oligomer binding
sites in all three HSA domains is instead more reminiscent
of the binding of fatty acids, for which the binding sites
are spread over all three albumin domains (Fig. 1 a). This
observation suggests that albumin may target hydrophobic
residues in Ab and also provides a possible explanation
for the marked selectivity of albumin toward the Ab oligo-
mers (i.e., KD < mM) relative to the Ab monomers (i.e.,
KD R mM) (4). In the monomeric Ab peptide the central
hydrophobic residues are shielded by intramolecular
FIGURE 6 Schematic model to summarize the prevailing stoichiome-
tries and affinities for the complexes between HSA and the Ab protofibrils.
The structures of apo albumin (PDB file 1AO6) and of the Ab protofibrils
(PDB file 2BEG) were used to generate a model with reliable relative
scales. The curved dashed lines indicate possible steric hindrance between
Ab protofibrils binding to different domains. The black solid lines are used
as an aid in the comparison of the sizes of the albumin domains and of Ab
protofibril. The dashed arrows indicate the direction of protofibril growth
while 44 A˚ corresponds to the protofibrils width. The C-terminal hydro-
phobic residues are depicted in black, whereas hydrophobic residues in
the central hydrophobic core (CHC) are indicated in dark gray. Although
a single Ab protofibril is shown per albumin domain, we cannot rule out
based on our data the presence of additional Ab protofibrils.
Ab-HSA Stoichiometry and Affinity 191hydrophobic contacts (25,26), which compete with intermo-
lecular interactions with HSA. However, it has been shown
(27) that in the Ab protofibrils several hydrophobic residues
of Ab become solvent-exposed and therefore potentially
available to interact with HSA. It is also possible that the
Ab protofibrils preorganize these hydrophobic side chains
for their recognition by albumin. This protofibril-specific
preorganization would significantly minimize the entropic
loss that would otherwise occur if HSA bound Ab mono-
mers, which unlike protofibrils populate a structurally
diverse ensemble of conformations in dynamic equilibrium
(25,26).
A second notable feature of our model (Fig. 6) is that the
HSA domains bind Ab oligomers with an affinity in the
1–100 nM range, which is higher than that reported for
most low MW HSA ligands (10). This marked difference
in affinity is fully consistent with the different physiological
functions of the HSA interactions with Ab as opposed to
other ligands. Albumin functions as a delivery reservoir
for FAs and exogenous ligands and therefore the binding
of these molecules to HSA requires reversibility. This is
why the carrier function of albumin is optimally imple-mented through affinities in the mM range. On the contrary,
when HSA functions as an Ab fibrilization inhibitor, no
binding reversibility is warranted. As a consequence, albu-
min binds Ab oligomers with KD < mM, minimizing Ab
oligomer release and ensuring an effective inhibition of
Ab fibril deposition. Furthermore, the nM affinity observed
here between HSA and the Ab assemblies explains also why
the majority of Ab in blood plasma is bound to albumin (6).
The Ab peptide is present in human plasma at ~nM concen-
trations (6,28) and the previously reported IC50 value of
~10 mM for the Ab fibrilization inhibition by HSA (7)
cannot explain alone why the large majority (89%) of Ab
in plasma is bound to albumin (6). It is possible that the
previously reported IC50 measurement was limited by the
amount of Ab fibrils used in the experiments and therefore
it provides only a broad upper limit for the actual affinity of
albumin toward Ab assemblies.
The third key implication of our proposed model (Fig. 6)
is that, while each HSA molecule can bind multiple Ab
oligomers, each Ab oligomer binds only a single HSA
molecule in the prevailing stoichiometry. This DLS- and
EM-based conclusion is independently supported by the
structure of Ab protofibril proposed by Lu¨hrs et al. (27).
Based on this structure, only a single extended patch of
exposed hydrophobic residues is present in the Ab protofi-
bril and it is located at a site referred to as the odd protofibril
edge (27). The protofibril odd-edge is not only a locus for
monomer recognition, and therefore a protofibril-growing
site, but it is also a site available for interactions with
possible inhibitors (27), such as HSA. The presence of a
single albumin binding site within each Ab protofibril
in vitro is therefore supported by our DLS data and by inde-
pendent structural evidence. Furthermore, this conclusion is
expected to be relevant in vivo as well, because if more than
a single albumin binding site was present within each Ab
protofibril, then the albumin-Ab interactions could easily
lead to the formation of extended polymerlike aggregates
and actually promote the formation of insoluble deposits.
Overall, we conclude that the affinities and the stoichio-
metric ratios of the proposed model for the albumin-Ab
interactions (Fig. 6) appear to be functional to the effective
inhibition by HSA of Ab fibrilization. In addition, the exper-
imental strategies integrating NMR, DLS, ultrafiltration,
and deletion mutagenesis as well as the Scatchard-like
modeling of inhibition outlined here are expected to be of
general applicability to other systems composed of amyloid
inhibitors and amyloidogenic peptides (29,30).SUPPORTING MATERIAL
Materials andmethods, one equation, one table, and sixfigures are available at
http://www.biophysj.org/biophysj/supplemental/S0006-3495(10)01435-9.
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